ALTABAX
LOE ApproachingNDATOPICALOINTMENT
Approved
Apr 2007
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
4
Data completeness
5/8 — Partial
ALTABAX by Almirall is 12. First approved in 2007.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALTABAX (retapamulin) is a topical antibacterial ointment approved in 2007 that selectively inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It is indicated for impetigo, atopic dermatitis, folliculitis, and eczema caused by Staphylococcus aureus and Streptococcus pyogenes. The drug demonstrates bacteriostatic activity at therapeutic concentrations and shows no cross-resistance with other antibiotic classes.
$0.074MPart D
LOE Approaching9mo to LOEWith loss of exclusivity approaching in February 2027 and minimal Part D utilization ($74K, 122 claims in 2023), the ALTABAX brand team faces significant contraction and will prioritize generic transition planning.
Mechanism of Action
12.1 Mechanism of Action ALTABAX is an antibacterial agent [see Clinical Pharmacology (12.4)] . 12.2 Pharmacodynamics In post-hoc analyses of manually over-read 12-lead ECGs from healthy subjects (N = 103), no significant effects on QT/QTc intervals were observed after topical application of…
Worked on ALTABAX at Almirall? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.